Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901

Michael P. Manns, Ulus S. Akarca, Ting Tsung Chang, William Sievert, Seung Kew Yoon, Naoky Tsai, Albert Min, Andreas Pangerl, Suzanne Beebe, Miao Yu, Suchat Wongcharatrawee

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association. Methods: The open-label study ETV-901 (AI463901) assessed the safety of entecavir in chronic hepatitis B patients who received entecavir, lamivudine or adefovir monotherapy in previous entecavir Phase II/III studies. Long-term cumulative safety results are based on reported AEs, regardless of causal relationship. Results: Median exposure to entecavir in study ETV-901 was 184 weeks. Commonly reported AEs (≥ 10%) were upper respiratory tract infection, headache and nasopharyngitis. Most AEs were mild to moderate; 203 (19%) patients reported grade 3 4 AEs, with 45 (4%) considered related to entecavir. There were 14 (1%) discontinuations due to AEs. On-treatment alanine aminotransferase (ALT) flares were reported in 32 (3%) patients and were associated with a reduction in hepatitis B virus DNA of more than 2 log10 copies/ml in 25/32 patients. AEs potentially associated with nucleos(t)ide analogs were infrequent, the most common being myalgia (n = 54; 5%) and neuropathy-related AEs (hypoparesthesia and hyperparesthesia, polyneuropathy; n = 42; 4%). Conclusions: Long-term administration of entecavir was associated with low rates of serious AEs, discontinuations due to AEs and ALT flares. AEs potentially associated with nucleos(t)ide use occurred at low rates.

Original languageEnglish
Pages (from-to)361-368
Number of pages8
JournalExpert Opinion on Drug Safety
Volume11
Issue number3
DOIs
Publication statusPublished - 2012 May 1

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901'. Together they form a unique fingerprint.

  • Cite this

    Manns, M. P., Akarca, U. S., Chang, T. T., Sievert, W., Yoon, S. K., Tsai, N., Min, A., Pangerl, A., Beebe, S., Yu, M., & Wongcharatrawee, S. (2012). Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opinion on Drug Safety, 11(3), 361-368. https://doi.org/10.1517/14740338.2012.653340